Schwannomas in patients with germline SMARCB1 mutations have been reported to exhibit a mosaic SMARCB1 protein expression pattern by immunohistochemical staining of tumour sections with the monoclonal BAF47 antibody specific for the C-terminal part of SMARCB1 raised against amino acids 257–359 (Hulsebos et al. 2007; Patil et al. 2008; Smith et al. 2012c). Here, SMARCB1 is linked to schwannoma.